Emergent Reports Explosive Revenue Growth of Over 100% for Quarter Ended December 31st, 2022

Emergent Health Corp. (OTC PINK:EMGE), a leading provider of innovative products in the Regenerative Health Space, has reported an impressive 100% quarter-over-quarter revenue increase for the quarter ending December 31st, 2022, with revenues of approximately $408,000 compared to the previous quarter’s $185,000. This financial statement will be available to view in its entirety on OTC Markets on/or before March 31st, 2023.

Regenerative medicine is revolutionizing the medical landscape by providing a revolutionary application in the form of stem cell therapy. This therapy encourages the repair of damaged tissue by stimulating the regeneration of cells, rather than relying on donor organs. Scientists cultivate the stem cells in a laboratory and allow them to specialize into particular cells, such as heart muscle or nerve cells, before being implanted into an individual. The potential of stem cells to restore all types of tissue in the human body has made them popular in tissue repair and regeneration, making them one of the most sought-after medical treatments of the future. By 2030, the global regenerative medicine market is predicted to be worth USD 125.54 billion, registering a CAGR of 16.2% from 2022 to 2030.

Morrison, President of L’Oréal and current CEO of Emergent, beamed with pride as Evolutionary Biologics closed out the fourth quarter of 2022 with tremendous growth. He predicted 2023 will see the launch of a plethora of exciting new products and services, particularly in the aesthetics sector.


Emergent is a leading provider of regenerative health products, including ingestibles and topicals for the whole family. Its products are distributed online and through Content Based Shopping, leveraging Influencers to drive product awareness across the US and internationally. Its subsidiaries, PharmaZu, Regen BioWellness and Evolutionary Biologics, are focused on the pet community, pet pharmacy, vet telehealth and pet wellness, as well as plant-based and regenerative medical fields. Emergent’s products are not approved by the FDA to diagnose, treat, cure or prevent any disease, but they do provide cutting-edge regenerative products to the medical community. To learn more, please visit Emergent’s website and follow them on Twitter and Linkedin.

Before you begin using any products, it’s important to seek advice from your veterinarian and/or family doctor. Doing so can help ensure that you’re utilizing the best treatment options for your pet or yourself.


Our future looks bright! We have the potential to enhance our products and systems to keep up with industry changes, expand our customer base and retain existing customers, effectively compete in our market segment, and raise sufficient capital to fund our business operations. Despite the lack of public information on our company, and the limited public market for our common stock.

Leave a Comment